All Cardiovascular disease articles
-
VideoSecondary event prevention and risk stratification in patients with symptomatic peripheral arterial disease (PAD)
Information intended for healthcare professionals only. The development of this Guidelines in Practice video has been commissioned by Bayer plc. Please see the bottom of the page for full disclaimer. View prescribing information Video: Secondary event prevention and risk stratification in patients ...
-
Video
Secondary event prevention and risk stratification in patients with stable coronary artery disease (CAD)
Information intended for healthcare professionals only. The development of this Guidelines in Practice video has been commissioned by Bayer plc. Please see the bottom of the page for full disclaimer. View prescribing information Video: Secondary event prevention and risk stratification in patients ...
-
Supplement
Management of Type 2 Diabetes and Cardiovascular Disease
Information intended for healthcare professionals only. This supplement has been commissioned and funded by Boehringer Ingelheim Limited and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice . Please see the bottom of the page for full disclaimer. View prescribing information Download ...
-
Checklist
Implementing the ADA and EASD 2018 consensus report: management of hyperglycaemia in type 2 diabetes
Information intended for healthcare professionals only. This checklist has been commissioned and funded by Boehringer Ingelheim Limited and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice . Please see the bottom of the page for full disclaimer. View prescribing information If the PDF does not ...
-
Formulary decision guide
Jardiance® (empagliflozin) film-coated tablets
This formulary decision guide was initiated, funded, and reviewed by Boehringer Ingelheim Limited and Lilly Diabetes Alliance. The format was developed by Guidelines in Practice. View prescribing information Key points on this medicine Jardiance: is a once-daily SGLT2 inhibitor that improves ...
-
Test and reflect
SIGN guideline on pharmacological management of type 2 diabetes
This CPD activity consists of 5 multiple-choice questions (MCQs) designed to test your knowledge on SIGN guideline recommendations on managing type 2 diabetes—you will then be prompted to reflect on your learning.
-
Implementing guidelines
Cardiac rehabilitation should be individualised to meet patient needs
Dr Alan Begg explores updated SIGN recommendations on cardiac rehabilitation and strategies that encourage patient engagement in lifestyle risk factor management, psychosocial wellbeing, and behaviour change.
-
Implementing guidelines
Estimating cardiovascular risk is key to preventing disease
Dr Alan Begg summarises new SIGN guidance and explains why lifestyle change is an essential aspect of cardiovascular risk reduction
-
Top tips
Top tips: venous thromboembolism
Dr Alan Begg discusses the diagnosis, assessment, and management of thromboembolic disease in primary care
-
News
SIGN releases updated guidance on cardiovascular disease
The Scottish Intercollegiate Guidelines Network (SIGN) has published SIGN 149 Risk estimation and the prevention of cardiovascular disease and SIGN 150 Cardiac rehabilitation.
-
NICE quality standard article
Primary care needs a strategy to help identify CVD risk
Dr Ivan Benett shows how NICE has prioritised guidance on cardiovascular risk assessment and lipid modification into a quality standard to improve patient outcomes and experience
-
Personal view
Should everyone with a 10% risk of CVD take a statin?
Dr Terry McCormack revisits recent controversies about NICE guidance on statins and offers patient scenarios illustrating his own approach in clinical practice
-
Implementing guidelines
JBS3 guideline focuses on both short-term and lifetime risk of CVD
Professor John Deanfield explains how the JBS3 approach to CVD risk reduction encompasses the whole population rather than just those individuals at high short-term risk
-
Personal view
Lifetime CVD risk calculator invites earlier interventions
Dr Alan Begg summarises key aspects of JBS3 that are relevant to primary care and considers some implications for clinical practice
-
GMS contract
Primary prevention of CVD is given greater prominence in QOF
Dr Alan Begg explains how the QOF indicators for 2011/2012 have been updated to improve identification of cardiovascular risk in people with serious mental illness
-
Implementing guidelines
Controlling triglyceride levels can reduce risk of CVD and pancreatitis
Dr Honor Merriman discusses how a recently published consensus guideline should help healthcare professionals to assess and manage patients with hypertriglyceridaemia
-
GMS contract
Risk assessment can help in the primary prevention of CVD
Dr Alan Begg explains how QOF-driven identification of patients with hypertension, along with NICE guidance and screening programmes, can help to reduce CVD prevalence
-
Personal view
Lowering cholesterol levels reduces CVD mortality
Dr Alan Begg discusses how the NICE technology appraisal on ezetimibe will make it easier for GPs to reach QOF cholesterol targets
-
Good practice initiative
Patients benefit from a simple CVD risk recording project
Dr Zaid Albrefkany’s winning team in the 2007 Guidelines in Practice Cardiovascular Disease Award set up an audit of CVD risk recording, which led to targeted treatment of high-risk patients
-
Implementing guidelines
Guideline highlights association of erectile dysfunction and CVD
The evidence-based guideline on erectile dysfunction from the BSSM will help the primary care team manage this common condition, explains Dr Geoff Hackett
